兼顾基础与餐后血糖控制 智飞生物子公司CA508注射液Ⅲ期临床告捷

Core Viewpoint - The announcement by Zhifei Biological indicates a significant breakthrough in the treatment of metabolic diseases, specifically with the completion of Phase III clinical trials for the CA508 insulin injection, which lays the groundwork for future market approval [1] Group 1: Clinical Trial Results - The CA508 injection, developed by the subsidiary Chuanan Biological, has completed Phase III clinical trials and received a summary report, marking a key milestone for the company in the diabetes treatment sector [1] - The clinical trial was led by Peking University People's Hospital and involved 40 domestic research centers, focusing on Type 2 diabetes patients with inadequate insulin treatment [1] - Results show that CA508 injection is comparable in efficacy and safety to the original drug (NovoRapid®), meeting relevant guidelines and providing core evidence for registration [1] Group 2: Product Details - CA508 injection is a new generation of basal-bolus insulin formulation, combining degludec insulin and aspart insulin, which allows for dual control of basal and postprandial blood glucose levels [1] - The formulation is a clear solution that requires 1-2 daily injections without the need for mixing, enhancing patient compliance [1] Group 3: Market Implications - Currently, there is only one other similar product approved in the domestic market aside from the original drug, indicating a potential competitive advantage for CA508 if approved [1] - The successful launch of CA508 injection would further solidify the company's integrated "prevention & treatment" strategy, strengthening its market position and industry competitiveness [1]